At the European Hematology Association (EHA) 2024 conference, MDS specialists presented phase 2 trial updates on the FDA-approved medicine elritercept, focusing on its effectiveness in reducing MDS-related anemia and iron overload. Read the key findings below.
Elritercept (KER-050, Keros Therapeutics) is a recently FDA-approved medicine for low—to intermediate-risk MDS patients that helps improve anemia and iron overload. It works by limiting cell signals that cause low blood cell production, thereby increasing blood counts.
The KER050-MD-201 study is still recruiting participants, but the first results in 60 low-risk MDS patients treated with elritercept over 24 weeks showed:
Another interesting finding from this study was that elritercept helped reduce the amount of stored iron. This is beneficial because excess iron in the body negatively impacts the bones’ ability to make blood cells, potentially leading to bone loss.
Elritercept addresses this issue by promoting blood cell growth, such as red blood cells. Red blood cells use stored iron, mitigating iron overload.
Although elritercept is FDA-approved, further data from the study will help provide more information about how this medicine affects low-risk MDS patients. If you want to review your eligibility to join the ongoing KER050-MD-201 study, click here.
Early findings from the KER050-MD-201 study show that elritercept is generally safe for low-risk MDS patients. It also has the potential to improve patients’ blood cell counts, alleviate certain symptoms of anemia, and reduce iron overload. More research from this study will provide additional findings regarding elritercept’s effectiveness in myelodysplastic syndromes.
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in myelodysplastic syndromes.
JOIN THE HEALTHTREE FOR MDS NEWSLETTER
Sources:
At the European Hematology Association (EHA) 2024 conference, MDS specialists presented phase 2 trial updates on the FDA-approved medicine elritercept, focusing on its effectiveness in reducing MDS-related anemia and iron overload. Read the key findings below.
Elritercept (KER-050, Keros Therapeutics) is a recently FDA-approved medicine for low—to intermediate-risk MDS patients that helps improve anemia and iron overload. It works by limiting cell signals that cause low blood cell production, thereby increasing blood counts.
The KER050-MD-201 study is still recruiting participants, but the first results in 60 low-risk MDS patients treated with elritercept over 24 weeks showed:
Another interesting finding from this study was that elritercept helped reduce the amount of stored iron. This is beneficial because excess iron in the body negatively impacts the bones’ ability to make blood cells, potentially leading to bone loss.
Elritercept addresses this issue by promoting blood cell growth, such as red blood cells. Red blood cells use stored iron, mitigating iron overload.
Although elritercept is FDA-approved, further data from the study will help provide more information about how this medicine affects low-risk MDS patients. If you want to review your eligibility to join the ongoing KER050-MD-201 study, click here.
Early findings from the KER050-MD-201 study show that elritercept is generally safe for low-risk MDS patients. It also has the potential to improve patients’ blood cell counts, alleviate certain symptoms of anemia, and reduce iron overload. More research from this study will provide additional findings regarding elritercept’s effectiveness in myelodysplastic syndromes.
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in myelodysplastic syndromes.
JOIN THE HEALTHTREE FOR MDS NEWSLETTER
Sources:
about the author
Megan Heaps
Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family, sewing, and cooking.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.